文献速递消化系统肿瘤

白蛋白紫杉醇治疗难治性小肠腺癌及CIMP高结直肠癌的II期研究

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

本II期研究评估白蛋白紫杉醇在难治性小肠腺癌(SBA)与CpG岛甲基化表型高(CIMP-high)转移性结直肠癌(CRC)中的敏感性;主要终点为RECIST 1.1缓解率。CIMP-high CRC队列未见缓解,SBA队列见2例部分缓解,SBA队列中位无进展生存期显著长于CIMP-high CRC队列(3.2个月 vs 2.1个月,P=0.03)。研究者结论为白蛋白紫杉醇在CIMP-high转移性CRC中无效,可能成为SBA的新治疗选择。

要点

  • CIMP-high转移性CRC队列未见客观缓解。
  • SBA队列见2例部分缓解。
  • SBA中位PFS 3.2个月 vs CIMP-high CRC 2.1个月(P=0.03)。

核心结论

  • 白蛋白紫杉醇在CIMP-high转移性结直肠癌中无效,可能成为小肠腺癌的新治疗选择。

研究设计与样本

  • 主要终点为RECIST 1.1缓解率,入组要求ECOG体能状态0/1、难治性疾病、SBA或CIMP-high转移性CRC。
  • 白蛋白紫杉醇初始剂量260 mg/m2每3周一次,后因毒性降至220 mg/m2。

主要发现

  • CIMP-high CRC队列未见缓解,SBA队列见2例部分缓解。
  • SBA队列中位无进展生存期显著长于CIMP-high CRC队列(3.2个月 vs 2.1个月,P=0.03)。
  • 常见3或4级毒性为乏力(12%)、中性粒细胞减少(9%)、发热性中性粒细胞减少(9%)、脱水(6%)、血小板减少(6%)。
  • 在CIMP-high CRC队列中,APC突变状态与CHFR甲基化状态均与疗效无关。
  • SBA患者来源异种移植瘤的体内紫杉醇试验验证了紫杉烷类在该病种中的活性。

关键数值与推荐

  • 主要终点为RECIST 1.1缓解率。
  • 白蛋白紫杉醇初始剂量260 mg/m2每3周一次,后因毒性降至220 mg/m2。
  • 疗效可评估人群定义为接受至少3剂治疗的患者。
  • SBA队列中位PFS 3.2个月 vs CIMP-high CRC队列2.1个月(P=0.03)。

临床怎么用

  • 对于难治性CIMP-high转移性CRC,本研究未观察到白蛋白紫杉醇的缓解。
  • 对于难治性SBA,白蛋白紫杉醇显示出部分缓解及较长的中位PFS,可能作为新的治疗选择。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypermethylation of promoter CpG islands [CpG island methylator phenotype (CIMP)] represents a unique pathway for the development of colorectal cancer (CRC), characterized by lack of chromosomal instability and a low rate of adenomatous polyposis coli (APC) mutations, which have both been correlated with taxane resistance. Similarly, small bowel adenocarcinoma (SBA), a rare tumor, also has a low rate of APC mutations. This phase II study evaluated taxane sensitivity in SBA and CIMP-high CRC. PATIENTS AND METHODS: The primary objective was Response Evaluation Criteria in Solid Tumors version 1.1 response rate. Eligibility included Eastern Cooperative Oncology Group performance status 0/1, refractory disease, and SBA or CIMP-high metastatic CRC. Nab-paclitaxel was initially administered at a dose of 260 mg/m2 every 3 weeks but was reduced to 220 mg/m2 owing to toxicity. RESULTS: A total of 21 patients with CIMP-high CRC and 13 with SBA were enrolled from November 2012 to October 2014. The efficacy-assessable population (patients who received at least three doses of the treatment) comprised 15 CIMP-high CRC patients and 10 SBA patients. Common grade 3 or 4 toxicities were fatigue (12%), neutropenia (9%), febrile neutropenia (9%), dehydration (6%), and thrombocytopenia (6%). No responses were seen in the CIMP-high CRC cohort and two partial responses were seen in the SBA cohort. Median progression-free survival was significantly greater in the SBA cohort than in the CIMP-high CRC cohort (3.2 months compared with 2.1 months, P = 0.03). Neither APC mutation status nor CHFR methylation status correlated with efficacy in the CIMP-high CRC cohort. In vivo testing of paclitaxel in an SBA patient-derived xenograft validated the activity of taxanes in this disease type. CONCLUSION: Although preclinical studies suggested taxane sensitivity was associated with chromosomal stability and wild-type APC, we found that nab-paclitaxel was inactive in CIMP-high metastatic CRC. Nab-paclitaxel may represent a novel therapeutic option for SBA.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Overman MJ, Adam L, Raghav K, et al. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol. 2018. PMID: 29069279. doi:10.1093/annonc/mdx688

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。